



# TORPEDO-CF

Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis

## How can the study help CF patients?

Cystic Fibrosis (CF) patients are at risk of developing infection in their lungs which can cause health problems.

*Pseudomonas aeruginosa* (PsA) is a common cause of infection.

New isolations of PsA are treated with antibiotics in an attempt to get rid of the germ. Antibiotics are either given orally (by mouth) or intravenously (by a tube into the vein), both are usually given in conjunction with inhaled antibiotics via a nebuliser.



The TORPEDO-CF study has been designed to compare the two treatments and find out whether there is any difference between them.

The results of this study can then be used to help doctors decide which treatment type should be used to treat new isolations of PsA.

## What happens to data collected for the study?

The purple sections below indicate current study activity. The green sections will not commence until our patient recruitment target is reached.


### Progress so far.....

On 5th November 2013 the **140th** patient was recruited by the adult team at Birmingham Heartlands Hospital.



Heartlands adult team

The reason this is an important recruitment milestone is because it means we have now achieved **50%** of our target recruitment of **280** patients!



Message from Dr Simon Langton Hewer, clinical lead for the study  
 "I would like to extend a personal **thank you** to the participating children and adult patients as well as their families that have been involved with recruitment in to this trial. I am very grateful to you all for your support!"



### Contact Us

If you would like more information please either speak to your clinical team at site or contact us by email or via our website:

[www.torpedo-cf.org.uk](http://www.torpedo-cf.org.uk)  
[torpedo@liverpool.ac.uk](mailto:torpedo@liverpool.ac.uk)

